News | Cardiac Imaging | February 16, 2026

Peer-Reviewed Article Demonstrates Advantages of Hybrid IVUS-OCT Imaging

New academic data supports clinical and commercial value of hybrid imaging platform.

Peer-Reviewed Article Demonstrates Advantages of Hybrid IVUS-OCT Imaging

Feb. 13, 2026 — Conavi Medical Corp. recently highlighted the publication of new peer-reviewed research titled “Deep learning-based plaque characterization in hybrid IVUS-OCT images is superior to single-modality deep learning analysis and human experts: head-to-head comparison against histology,” published in Cardiovascular Research by the European Society of Cardiology.

The study analyzed IVUS-OCT images and matched histological sections from 10 cadaveric human hearts, demonstrating that a histology-trained hybrid IVUS-OCT deep-learning classifier outperformed single-modality IVUS, single-modality OCT, and expert readers in plaque characterization, supporting the clinical and commercial value of a comprehensive hybrid imaging for enhancing treatment planning.

The patented Novasight Hybrid System combines intravascular ultrasound (IVUS) and optical coherence tomography (OCT) into a single device, enabling simultaneous and co-registered imaging of coronary arteries.

The publication includes contributions from Dr. Brian Courtney, a pioneer in hybrid IVUS-OCT imaging and co-inventor of the foundational hybrid imaging technology that underpins Conavi’s platform. Co-authors included imaging experts in Canada, Europe and the USA, as well as artificial intelligence researchers at Queen Mary University of London.

“Peer-reviewed academic research continues to reinforce the clinical value proposition behind Conavi’s technology platform,” said Tom Looby, Chief Executive Officer of Conavi Medical. “As the field moves toward more precise, image-guided coronary interventions, research highlighting the complementary strengths of IVUS and OCT underscores the importance of comprehensive hybrid systems.”

Conavi is advancing the development and commercialization of its next-generation hybrid IVUS-OCT imaging solutions and has submitted its next-generation Novasight imaging system to the U.S. Food and Drug Administration (FDA) for regulatory clearance, while continuing preparations to support commercialization and clinical adoption.

For additional details, the publication can be accessed at:
https://academic.oup.com/cardiovascres/advance-article-abstract/doi/10.1093/cvr/cvaf281/8443065

Go to www.conavi.com/novasight/ to learn more.


Additional Content

News | ESC

Aug. 28, 2026 — At ESC Congress in Munich, the European Society of Cardiology released its first updated heart failure ...

Home August 28, 2026
Home
News | ESC

Aug. 20, 2026 — Bayer has announced that 11 oral presentations across its cardiovascular, kidney, and secondary stroke ...

Home August 20, 2026
Home
News | ESC

July 23, 2026 — The results of 59 ground-breaking trials will be unveiled for the first time at ESC Congress 2026, the ...

Home July 27, 2026
Home
News | ESC

June 23, 2026 — The European Society of Cardiology (ESC) Congress 2026 will take place in Munich Aug. 28–31, 2026. ESC ...

Home June 23, 2026
Home
News | ESC

Aug. 28, 2025 — A new global systematic literature review and meta-analysis has shown that herpes zoster vaccination ...

Home August 29, 2025
Home
Subscribe Now